Navigation Links
Researchers implicate well-known protein in fibrosis
Date:11/20/2012

Chicago --- An international multi-disciplinary research team led by Northwestern Medicine scientists has uncovered a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis, or scarring.

This finding, recently reported in the American Journal of Pathology, has implications for the treatment of scleroderma, a condition for which there currently is no effective treatment.

TLR4 was previously implicated in inflammation, but its role in tissue fibrosis was unknown. Fibrosis is a hallmark of scleroderma and contributes to a range of common diseases including pulmonary fibrosis, kidney fibrosis, liver cirrhosis and radiation-induced scarring.

"We found that when the gene for TLR4 was mutated in mice, the mice became resistant to experimental scleroderma," said the study's first author Swati Bhattacharyya, research assistant professor of rheumatology at Northwestern University Feinberg School of Medicine. "Moreover, scleroderma patients showed abnormal TLR4 levels in fibrotic skin and lung tissue. This tells us we have found a therapeutic target."

Scleroderma is a chronic autoimmune disease which causes progressive tightening of the skin and can lead to serious internal organ damage and, in some cases, death. Scleroderma affects an estimated 300,000 people in the U.S., most frequently young-to-middle-aged women. Its cause and pathogenesis are unknown.

"The Northwestern research team continues to make fundamental discoveries that enhance our scientific understanding of scleroderma," said co-author John Varga, M.D., the John and Nancy Hughes Distinguished Professor of Rheumatology and professor of dermatology at Feinberg. "Careful dissection of the role of individual proteins in this disease enables us to make real progress toward novel treatments."

Researchers from Northwestern, Boston University, the University of Pittsburgh and the University Medical Center Nijmegen, Netherlands contributed to the study, which relied on tissue samples from human scleroderma patients and mouse models.

Agents that block TLR4 are already being developed for inflammation and sepsis in humans. Effective TLR4 inhibitor drugs may blunt and even possibly reverse the fibrosis in scleroderma, says Bhattacharyya. However, earlier attempts to develop therapeutics that block TLR4 have met with failure due to toxicity.

"These results, while significant, are preliminary. We now know that TLR4 plays a role in scleroderma, but much research remains to be done to develop safe and effective drugs to inhibit this pathway," she says.

The investigators are currently studying additional mouse models to better understand the role of TLR4 in fibrosis and are developing novel small molecules to selectively block TLR4 as a potential therapy.


'/>"/>
Contact: Marla Paul
marla-paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related medicine news :

1. Researchers build synthetic membrane channels out of DNA
2. JTCC researchers play important role in groundbreaking study that may change transplant practices
3. Researchers use computer simulations to find true cost of HIV screenings
4. Sleeping Pill Linked to Hospital Falls, Researchers Say
5. Daycare has many benefits for children, but researchers find mysterious link with overweight
6. Researchers outline effective strategies to prevent teen depression and suicide
7. Researchers report potential new treatment to stop Alzheimers disease
8. Feinstein Institute researchers discover plant derivative
9. Sociology, economics researchers receive grant to study development across the human lifespan
10. Genital Injuries Common But Preventable, Researchers Say
11. Researchers identify impact of rheumatoid arthritis and lupus on joint replacement surgery outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 2017 , ... Only a few physicians were selected to receive the prestigious ... Clevens, MD, FACS . The founder and medical director of Clevens Face and ... at Yale, Harvard and the University of Michigan. He has served patients throughout Central ...
(Date:9/19/2017)... ... September 19, 2017 , ... Arizona-based ... as the President of its HealthBI division. McFarland will grow the organization’s ... , “Scott is a utility player who balances his day as a ...
(Date:9/19/2017)... ... September 19, 2017 , ... The American Board of Multiple ... for the discomforts and hidden dangers of foot fungus, particularly in the warm ... risk for developing fungal infections on the feet or toenails, the Board says. ...
(Date:9/19/2017)... ... September 19, 2017 , ... The Semper Fi Fund, ... announces the release of a series of videos and a compelling documentary that provide ... in the United States as part of its ongoing mission. , Each of the ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... of the annual PAINWeek National Conference. On October 7, at the Hilton Providence, ... and exciting program providing busy clinicians and allied healthcare practitioners with 6.0 hours ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017  ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical Supplies, ... supplier of medical equipment, supplies, drugs, vaccines, and specialty ... entered into an agreement to acquire Vantage Medical Supplies, ... in Holtsville, New York . ... supplying new and emerging medical practices, will operate under ...
Breaking Medicine Technology: